Search | Clinical Trials Finder

Conditions: Metabolic Syndrome
Interventions: Professional nutrition counseling, No professional nutrition counseling; Other
Lead sponsor: Madigan Army Medical Center; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Neoplasms
Interventions: Dostarlimab; Biological
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 729 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 48
States / cities: Birmingham, Alabama • Goodyear, Arizona • Scottsdale, Arizona + 38 more

Conditions: Gastric Cancer, Breast Cancer, Cervical Cancer, Lung Cancer
Interventions: KK-LC-1 TCR-T cells, Aldesleukin; Biological · Drug
Lead sponsor: Christian Hinrichs; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 2
States / cities: New Brunswick, New Jersey

Conditions: Lysosomal Storage Diseases, Cystinosis
Interventions: CTNS-RD-04 (including CTNS-RD-04-LB manufactured with LentiBOOST); Genetic
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Brain Tumor Adult
Interventions: DRI cell therapy; Biological
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoma, Myelodysplastic Syndromes
Interventions: BPX-501 dose 1, Rimiducid, BPX-501 dose 2, BPX-501 dose 3, BPX-501 dose 4, SCT; Biological · Drug · Procedure
Lead sponsor: Bellicum Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2032
U.S. locations: 8
States / cities: Atlanta, Georgia • Buffalo, New York • New York, New York + 4 more

Conditions: Prostate Cancer
Interventions: Sargramostim (GM-CSF, Leukine), Flutamide (Eulexin), PROSTVAC-F/ TRICOM, PROSTVAC-V/TRICOM; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 110 Years · Male only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 3
States / cities: Bethesda, Maryland • New Brunswick, New Jersey • Philadelphia, Pennsylvania

Conditions: Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Interventions: Nadofaragene Firadenovec, Gemcitabine, Docetaxel, Pembrolizumab; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 39
States / cities: Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 33 more

Conditions: Rheumatoid Arthritis (RA), Hidradenitis Suppurativa (HS)
Interventions: Long Term Safety Monitoring Procedures; Other
Lead sponsor: Sonoma Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 71 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2040
U.S. locations: 10
States / cities: San Francisco, California • Stanford, California • Aurora, Colorado + 5 more

Conditions: Giant Axonal Neuropathy (GAN)
Interventions: scAAV9/JeT-GAN; Genetic
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 10 Years to 25 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Lymphoma
Interventions: comparative genomic hybridization, cytogenetic analysis, fluorescence in situ hybridization, gene rearrangement analysis; Genetic
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 391 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 69
States / cities: Anniston, Alabama • La Jolla, California • San Diego, California + 52 more

Conditions: HIV
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 21 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Cancer, Metastatic Melanoma, Metastatic Renal Cancer
Interventions: Fludarabine, Cyclophosphamide, IL-12 & Anti-NY ESO1 TCR PBL; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Melanoma (Skin)
Interventions: aldesleukin, filgrastim, incomplete Freund's adjuvant, interleukin-2 gene, therapeutic tumor infiltrating lymphocytes, cyclophosphamide, fludarabine phosphate; Biological · Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: HIV, HIV Infections
Interventions: ZFN modified T cells, Structured Treatment Interruption; Biological · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: The Bronx, New York • Philadelphia, Pennsylvania

Conditions: Muscular Atrophy, Spinal
Interventions: Risdiplam; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 3 Months to 24 Months
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 10
States / cities: Little Rock, Arkansas • Madera, California • Palo Alto, California + 7 more

Conditions: SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis, Inflammatory Myopathy, Idiopathic, Myositis, Diffuse Cutaneous Systemic Sclerosis
Interventions: CTX112; Biological
Lead sponsor: CRISPR Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 9
States / cities: La Jolla, California • Redwood City, California • Chicago, Illinois + 6 more

Conditions: Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
Interventions: Biospecimen Collection, Cabozantinib S-malate, Imaging Procedure, Sapanisertib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Irvine, California • Orange, California • Portland, Oregon + 1 more

Conditions: Neuroblastoma
Interventions: gene-modified tumor cell vaccine therapy, interleukin-2 gene; Biological
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2007
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Capmatinib, Computed Tomography, Magnetic Resonance Imaging, Osimertinib, Ramucirumab; Procedure · Drug · Biological
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 454
States / cities: Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 360 more

Conditions: Leukemia
Interventions: Dose Level 1, Dose Level 2, Dose Level 3; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2010
U.S. locations: 3
States / cities: Houston, Texas

Conditions: HIV Infection
Interventions: VRX496-Modified Autologous T cells; Genetic
Lead sponsor: VIRxSYS Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2023
U.S. locations: 5
States / cities: Palo Alto, California • Norwalk, Connecticut • Miami, Florida + 2 more

Conditions: Neuroblastoma
Interventions: aldesleukin, therapeutic autologous lymphocytes, chemotherapy, ganciclovir; Biological · Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 1 Year to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 2
States / cities: Duarte, California • Seattle, Washington

Conditions: B-cell Chronic Lymphocytic Leukemia, Hematopoietic/Lymphoid Cancer, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
Interventions: carfilzomib, Cytokine Assessment, Pharmacodynamic Studies, Proteosome Inhibition Assessment, Pharmacogenomic Studies; Drug · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

Precision Nutrition Impact on Health-Related Behavior Change

Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer

Stem Cell Gene Therapy for Cystinosis

Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma

Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic

Intraneural Administration of scAAV9/JeT-GAN Into the Vagus Nerve for Patients With Giant Axonal Neuropathy (GAN)

Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma

Safety and Survival of Genetically Modified White Blood Cells in HIV-infected Twins The Gemini Study

Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer

Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma

Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine

Safety and Efficacy of T Cell Genetic Immunotherapy for HIV

Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma

Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)